Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 20, 2004. The report details corporate actions taken following the Annual General Meeting (AGM) held on May 17, 2004, specifically regarding share repurchases and director interests.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes and corporate governance updates.
- Share Repurchase: 100,000 Ordinary Shares purchased on May 19, 2004.
- Repurchase Price: 1,186.37 pence per share.
- Treasury Holdings: 12,732,000 shares held in treasury following the transaction.
- Shares in Issue: 5,920,653,707 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback authorized at the AGM. Additionally, the GSK Trust transferred 71,689 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction affects the interests of directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe as potential beneficiaries of the trust.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the total cost of the 100,000 share repurchase (100,000 shares x 1,186.37 pence).
- Confirm the updated total share count including treasury shares for diluted EPS calculations.
- Review the full AGM resolutions available via the UK Listing Authority for other special business items.
- Check subsequent filings for the impact of the share buyback on the company's cash position.